Research programme: chimeric antigen receptor T cell therapy - HaemaLogiXAlternative Names: CAR-T cell therapy - HaemaLogiX; KMA.CAR-T; LMA.CAR-T
Latest Information Update: 25 Aug 2015
At a glance
- Originator HaemaLogiX
- Developer HaemaLogiX; Westmead Institute for Medical Research
- Class CAR-T cell therapies
- Mechanism of Action Immunostimulants; T lymphocyte replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Multiple myeloma